- Home
- DHR vs GILD Comparison
DHR vs GILD Comparison
Compare DHR & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHR
- GILD
- Stock Information
- Founded
- DHR 1969
- GILD 1987
- Country
- DHR United States
- GILD United States
- Employees
- DHR N/A
- GILD N/A
- Industry
- DHR Industrial Machinery/Components
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHR Industrials
- GILD Health Care
- Exchange
- DHR Nasdaq
- GILD Nasdaq
- Market Cap
- DHR 145.0B
- GILD 145.4B
- IPO Year
- DHR N/A
- GILD 1992
- Fundamental
- Price
- DHR $216.90
- GILD $117.88
- Analyst Decision
- DHR Strong Buy
- GILD Buy
- Analyst Count
- DHR 17
- GILD 22
- Target Price
- DHR $247.75
- GILD $118.76
- AVG Volume (30 Days)
- DHR 4.7M
- GILD 7.3M
- Earning Date
- DHR 10-21-2025
- GILD 10-30-2025
- Dividend Yield
- DHR 0.59%
- GILD 2.68%
- EPS Growth
- DHR N/A
- GILD 496.80
- EPS
- DHR 4.87
- GILD 5.01
- Revenue
- DHR $24,268,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- DHR $4.46
- GILD $2.25
- Revenue Next Year
- DHR $5.41
- GILD $3.77
- P/E Ratio
- DHR $44.57
- GILD $23.52
- Revenue Growth
- DHR 2.21
- GILD 3.81
- 52 Week Low
- DHR $171.00
- GILD $86.08
- 52 Week High
- DHR $258.23
- GILD $124.61
- Technical
- Relative Strength Index (RSI)
- DHR 58.39
- GILD 50.25
- Support Level
- DHR $215.28
- GILD $118.71
- Resistance Level
- DHR $225.05
- GILD $121.58
- Average True Range (ATR)
- DHR 5.43
- GILD 2.78
- MACD
- DHR 0.98
- GILD -0.07
- Stochastic Oscillator
- DHR 44.94
- GILD 23.61
About DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).